# Edwards Lifesciences vs Takeda Pharmaceutical

URL: https://funkfolio.com/compare/ew-vs-tak

> Edwards Lifesciences ($60.6B, P/E 61.3) and Takeda Pharmaceutical ($69.1B, P/E 309) compared: size, valuation, margins, debt, cash and price change.

---

## Edwards Lifesciences vs Takeda Pharmaceutical

Edwards Lifesciences (EW), health care, and Takeda Pharmaceutical (TAK), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Takeda Pharmaceutical is worth $69.1B on the stock market and Edwards Lifesciences $60.6B: Takeda Pharmaceutical is valued at 14% more. Edwards Lifesciences trades at 61.3 times earnings and Takeda Pharmaceutical at 309; operating margins in their latest fiscal years were 20.8% and 0.14%. Over the past year Edwards Lifesciences's share price has moved +27.5% and Takeda Pharmaceutical's +53.4%.

### Key facts

- **Edwards Lifesciences market value:** $60.6B
- **Takeda Pharmaceutical market value:** $69.1B
- **Edwards Lifesciences P/E:** 61.3
- **Takeda Pharmaceutical P/E:** 309
- **Edwards Lifesciences revenue:** $6.1B FY to 2025-12-31
- **Takeda Pharmaceutical revenue:** $28.2B FY to 2026-03-31
- **Superinvestors holding both:** 0

Market values as of 18 Nov 2026, 03:50 UTC.

Edwards Lifesciences vs Takeda Pharmaceutical: every measure side by side

| Measure | Edwards Lifesciences | Takeda Pharmaceutical |
| --- | --- | --- |
| Sector | Health Care | Health Care |
| Country | United States | Japan |
| Fiscal year ends | 2025-12-31 | 2026-03-31 |
| Size |  |  |
| Market cap | $60.6B lower | $69.1B higher |
| Revenue | $6.1B lower | $28.2B higher |
| Earnings | $1.1B higher | -$954.4M lower |
| Employees | 16,000 lower | 47,029 higher |
| Total assets | $13.7B lower | $97.1B higher |
| Valuation |  |  |
| P/E | 61.3 lower | 309 higher |
| P/S | 10.0 higher | 2.5 lower |
| P/B | 5.6 | — |
| Dividend yield | 0.00% | — |
| Profitability |  |  |
| Operating margin | 20.8% higher | 0.14% lower |
| Balance sheet |  |  |
| Net assets | $10.3B lower | $46.5B higher |
| Total liabilities | $3.4B lower | $50.6B higher |
| Total debt | $598.3M lower | $30.6B higher |
| Cash on hand | $2.9B lower | $3.7B higher |
| Price change |  |  |
| Today | -1.57% lower | +0.23% higher |
| 1 year | +27.5% lower | +53.4% higher |

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

### Share price over one year

Each company's share price rebased to 100 on Nov 17, 2025, so the two lines start together. Price only: dividends are not included. Last: Edwards Lifesciences 124.4, Takeda Pharmaceutical 153.0.

- Edwards Lifesciences (EW)
- Takeda Pharmaceutical (TAK)

Edwards Lifesciences and Takeda Pharmaceutical share prices over one year, rebased to 100: Edwards Lifesciences ends at 124.4, Takeda Pharmaceutical at 153.0.

**The chart as a table**

Month-end share prices rebased to 100

| Month end | EW | TAK |
| --- | --- | --- |
| Nov 28, 2025 | 102.3 | 102.0 |
| Dec 31, 2025 | 100.6 | 110.3 |
| Jan 30, 2026 | 96.0 | 121.9 |
| Feb 27, 2026 | 102.0 | 132.6 |
| Mar 31, 2026 | 94.5 | 131.0 |
| Apr 30, 2026 | 98.5 | 118.0 |
| May 29, 2026 | 102.0 | 112.9 |
| Jun 30, 2026 | 106.8 | 113.4 |
| Jul 31, 2026 | 101.6 | 120.9 |
| Aug 31, 2026 | 107.1 | 127.2 |
| Sep 30, 2026 | 101.9 | 128.6 |
| Oct 30, 2026 | 108.6 | 147.9 |
| Nov 17, 2026 | 124.4 | 153.0 |

### Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

#### Both (0)

None of the tracked investors.

#### Edwards Lifesciences only (9)

- [David Rolfe](https://funkfolio.com/gurus/david-rolfe) 3.1%
- [Howard Gleicher](https://funkfolio.com/gurus/howard-gleicher) 1.6%
- [Brandon Haley](https://funkfolio.com/gurus/brandon-haley) 0.7%
- [Steve Cohen](https://funkfolio.com/gurus/steve-cohen) 0.2%
- [Israel Englander](https://funkfolio.com/gurus/israel-englander) 0.2%
- [Ken Griffin](https://funkfolio.com/gurus/ken-griffin) 0.2%
- [Primecap team](https://funkfolio.com/gurus/primecap) 0.2%
- [Baillie Gifford team](https://funkfolio.com/gurus/baillie-gifford) 0.1%
- [Ron Baron](https://funkfolio.com/gurus/ron-baron) 0.1%

#### Takeda Pharmaceutical only (2)

- [Charles Brandes (founder)](https://funkfolio.com/gurus/charles-brandes) 0.5%
- [Richard Pzena](https://funkfolio.com/gurus/richard-pzena) &lt;0.1%

Percentages are each holding's share of that investor's reported portfolio. [Who owns EW](https://funkfolio.com/stock/EW/superinvestors) · [Who owns TAK](https://funkfolio.com/stock/TAK/superinvestors)

### More on Edwards Lifesciences

- [Edwards Lifesciences (EW) stock page](https://funkfolio.com/stock/EW)
- [Edwards Lifesciences market cap](https://funkfolio.com/stock/EW/market-cap)
- [Edwards Lifesciences revenue](https://funkfolio.com/stock/EW/revenue)
- [Edwards Lifesciences P/E ratio](https://funkfolio.com/stock/EW/pe-ratio)
- [Edwards Lifesciences operating margin](https://funkfolio.com/stock/EW/operating-margin)
- [Edwards Lifesciences total debt](https://funkfolio.com/stock/EW/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### More on Takeda Pharmaceutical

- [Takeda Pharmaceutical (TAK) stock page](https://funkfolio.com/stock/TAK)
- [Takeda Pharmaceutical market cap](https://funkfolio.com/stock/TAK/market-cap)
- [Takeda Pharmaceutical revenue](https://funkfolio.com/stock/TAK/revenue)
- [Takeda Pharmaceutical P/E ratio](https://funkfolio.com/stock/TAK/pe-ratio)
- [Takeda Pharmaceutical operating margin](https://funkfolio.com/stock/TAK/operating-margin)
- [Takeda Pharmaceutical total debt](https://funkfolio.com/stock/TAK/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### Further comparisons

#### Edwards Lifesciences against its closest peers

- [Edwards Lifesciences vs argenx](https://funkfolio.com/compare/argx-vs-ew)
- [Edwards Lifesciences vs Becton, Dickinson](https://funkfolio.com/compare/bdx-vs-ew)
- [Edwards Lifesciences vs Cardinal Health](https://funkfolio.com/compare/cah-vs-ew)
- [Edwards Lifesciences vs Boston Scientific](https://funkfolio.com/compare/bsx-vs-ew)

#### Takeda Pharmaceutical against its closest peers

- [Takeda Pharmaceutical vs Cencora](https://funkfolio.com/compare/cor-vs-tak)
- [Takeda Pharmaceutical vs Boston Scientific](https://funkfolio.com/compare/bsx-vs-tak)
- [Takeda Pharmaceutical vs Cardinal Health](https://funkfolio.com/compare/cah-vs-tak)
- [Takeda Pharmaceutical vs argenx](https://funkfolio.com/compare/argx-vs-tak)

### Learn

- [What market capitalization is and is not](https://funkfolio.com/learn/markets/market-capitalization)
- [P/E ratio explained](https://funkfolio.com/learn/stocks/pe-ratio)
- [Market cap vs enterprise value](https://funkfolio.com/learn/markets/market-cap-vs-enterprise-value)

### Questions and answers

**Which is bigger, Edwards Lifesciences or Takeda Pharmaceutical?**

By market value, Takeda Pharmaceutical is the larger: $69.1B against $60.6B for Edwards Lifesciences. By revenue in its latest fiscal year, Takeda Pharmaceutical is the larger: $28.2B against $6.1B for Edwards Lifesciences.

**Which has the higher P/E ratio?**

Takeda Pharmaceutical: 309, against 61.3 for Edwards Lifesciences. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

**Which has the higher operating margin?**

Edwards Lifesciences: 20.8%, against 0.14% for Takeda Pharmaceutical. Operating margin is operating income as a share of revenue in the latest fiscal year.

**Which has more debt?**

Takeda Pharmaceutical: $30.6B, against $598.3M for Edwards Lifesciences. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

**Which superinvestors own both Edwards Lifesciences and Takeda Pharmaceutical?**

None of the tracked superinvestors holds both in their latest 13F filing. 9 hold Edwards Lifesciences and 2 hold Takeda Pharmaceutical.

### Cite this page

Funkfolio, “Edwards Lifesciences vs Takeda Pharmaceutical”, data as of 18 November 2026. https://funkfolio.com/compare/ew-vs-tak

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.
